Alopecia Drug Candidate Has Shown Hair Regrowth
New clinical trial results indicate that adults with alopecia areata may achieve significant hair regrowth with this treatment.
Updated on Oct. 13, 2026 in Allergies
Live Poll
Would you be willing to try an experimental hair regrowth treatment before long-term data exists?
In the phase 2b REZOLVE-AA trial, researchers found that participants receiving the drug rezpegaldesleukin experienced notable improvements in scalp hair coverage over 52 weeks. These preliminary findings were presented at the EADV Congress.
Why it matters
The study offers a potential new treatment pathway for adults with alopecia areata by using a novel approach to stimulate hair follicles. Understanding these results helps patients and clinicians monitor the development of therapies that move beyond existing standard options.
In a 92-participant phase 2b trial, adults with alopecia areata received subcutaneous doses of rezpegaldesleukin or a placebo every two weeks. At 52 weeks, 35% of high-dose recipients reached a SALT score of 30 or lower, compared to 8.4% of the placebo group.
The players
EADV Congress
A major scientific gathering for dermatologists and researchers to share advancements in skin health and treatment protocols.
The details
The treatment functions as an interleukin-2 receptor agonist designed to induce regulatory T cells, which helps modulate the immune system and promote hair regrowth. Participants with a SALT score above 20 at week 36 participated in a 16-week blinded extension period to assess continued efficacy. Researchers also analyzed a safety database of over 1,000 patients and found no increased risk of malignancy, conjunctivitis, or oral herpes.
Timeline
September 30-October 3, 2026: Results were presented at the EADV Congress in Vienna.
End of 2026: The phase 3 clinical program for the drug is scheduled to begin.
Health Landscape
The REZOLVE-AA trial represents an evolution in the treatment landscape for alopecia areata, shifting from broad immunosuppression to targeted immune regulation. This approach sits alongside current pipeline efforts to find long-term solutions for follicle preservation.
While these trial results are promising, they are currently preliminary and not yet peer-reviewed. Those interested in emerging options for hair loss should speak with a dermatologist to track when late-stage trial results become available.
The takeaway
Rezpegaldesleukin shows potential for hair regrowth in adults with alopecia areata through targeted immune modulation. Patients should follow updates on upcoming phase 3 trial enrollment to stay informed about potential future treatment availability.
What happens next
The phase 3 clinical program for rezpegaldesleukin is expected to commence by the end of 2026.
Further reading
Learn more about new research and approaches for Allergies.
More information
View the Clinical trial study details at the official registry.
Source note: This article includes information reported by Hcplive.
Live Poll
Would you be willing to try an experimental hair regrowth treatment before long-term data exists?
